KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Treasury Shares: 2020-2024

Historic Treasury Shares for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Dec 2024 value amounting to $8.0 million.

  • Aurinia Pharmaceuticals' Treasury Shares rose 258.82% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year increase of 258.82%. This contributed to the annual value of $8.0 million for FY2024, which is 2.29% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Treasury Shares of $8.0 million as of FY2024, which was up 2.29% from $7.8 million recorded in FY2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' Treasury Shares peaked at $14.0 million during FY2020, and registered a low of $347,000 during FY2021.
  • Moreover, its 3-year median value for Treasury Shares was $7.8 million (2023), whereas its average is $5.9 million.
  • Its Treasury Shares has fluctuated over the past 5 years, first tumbled by 97.53% in 2021, then soared by 470.61% in 2022.
  • Yearly analysis of 5 years shows Aurinia Pharmaceuticals' Treasury Shares stood at $14.0 million in 2020, then plummeted by 97.53% to $347,000 in 2021, then spiked by 470.61% to $2.0 million in 2022, then skyrocketed by 294.29% to $7.8 million in 2023, then climbed by 2.29% to $8.0 million in 2024.